Potentiated therapeutic angiogenesis by primed human mesenchymal stem cells in a mouse model of hindlimb ischemia

Regenerative Medicine

Volumn 8, Issue 3, 2013, Pages 283-293

  Lee, Eun Ju ^a   Park, Hwan Woo ^b   Jeon, Hyo Jin ^b   Kim, Hyo Soo ^a,c   Chang, Mi Sook ^b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

angiogenesis; ischemia; mesenchymal stem cells; paracrine effect; transplantation

Indexed keywords

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL THERAPY; DNA MODIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART INFARCTION; HINDLIMB; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; LEG ISCHEMIA; LIMB ISCHEMIA; LIMB SALVAGE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHWANN CELL; SURVIVAL; TISSUE PERFUSION;

ADULT; ANIMALS; DISEASE MODELS, ANIMAL; HEPATOCYTE GROWTH FACTOR; HINDLIMB; HUMANS; ISCHEMIA; LIMB SALVAGE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84876921999     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.13.17     Document Type: Article

References (47)

1. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 438(7070), 967-974 (2005).
2. Folkman J. Therapeutic angiogenesis in ischemic limbs. Circulation 97(12), 1108-1110 (1998).
3. Isner JM. Therapeutic angiogenesis: a new frontier for vascular therapy. Vasc. Med. 1(1), 79-87 (1996).
4. Griffin MD, Ritter T, Mahon BP. Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum. Gene Ther. 21(12), 1641-1655 (2010).
5. Rameshwar P. Casting doubt on the safety of "off-the-shelf" mesenchymal stem cells for cell therapy. Mol. Ther. 17(2), 216-218 (2009).
6. Sherman LS, Munoz J, Patel SA, Dave MA, Paige I, Rameshwar P. Moving from the laboratory bench to patients' bedside: considerations for effective therapy with stem cells. Clin. Transl. Sci. 4(5), 380-386 (2011).
7. Hamano K, Li TS, Kobayashi T et al. The induction of angiogenesis by the implantation of autologous bone marrow cells: a novel and simple therapeutic method. Surgery 130(1), 44-54 (2001).
8. Iwase T, Nagaya N, Fujii T et al. Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc. Res. 66(3), 543-551 (2005).
9. Shintani S, Murohara T, Ikeda H et al. Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation 103(6), 897-903 (2001).
10. Kinnaird T, Stabile E, Burnett MS et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ. Res. 94(5), 678-685 (2004).
11. Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380(6573), 435-439 (1996).
12. Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380(6573), 439-442 (1996).
13. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 407(6801), 242-248 (2000).
14. Bussolino F, Di Renzo MF, Ziche M et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol. 119(3), 629-641 (1992).
15. Park HW, Lim MJ, Jung H, Lee SP, Paik KS, Chang MS. Human mesenchymal stem cell-derived Schwann cell-like cells exhibit neurotrophic effects, via distinct growth factor production, in a model of spinal cord injury. Glia 58(9), 1118-1132 (2010).
16. Couffinhal T, Silver M, Zheng LP, Kearney M, Witzenbichler B, Isner JM. Mouse model of angiogenesis. Am. J. Pathol. 152(6), 1667-1679 (1998).
17. Lee SW, Jeong HK, Lee JY et al. Hypoxic priming of mESCs accelerates vascular-lineage differentiation through HIF1- mediated inverse regulation of Oct4 and VEGF. EMBO Mol. Med. 4(9), 924-938 (2012).
18. Lin CS, Lin G, Lue TF. Allogeneic and xenogeneic transplantation of adipose-derived stem cells in immunocompetent recipients without immunosuppressants. Stem Cells Dev. 21(15), 2770-2778 (2012).
19. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4), 315-317 (2006).
20. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 19(3), 180-192 (2001).
21. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 284(5411), 143-147 (1999).
22. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276(5309), 71-74 (1997).
23. Galmiche MC, Koteliansky VE, Briere J, Herve P, Charbord P. Stromal cells from human long-term marrow cultures are mesenchymal cells that differentiate following a vascular smooth muscle differentiation pathway. Blood 82(1), 66-76 (1993).
24. Prockop DJ. "Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin. Pharmacol. Ther. 82(3), 241-243 (2007).
25. van Weel V, van Tongeren RB, van Hinsbergh VW, van Bockel JH, Quax PH. Vascular growth in ischemic limbs: a review of mechanisms and possible therapeutic stimulation. Ann. Vasc. Surg. 22(4), 582-597 (2008).
26. Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7(4), 430-436 (2001).
27. Takahashi T, Kalka C, Masuda H et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 5(4), 434-438 (1999).
28. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302), 964-967 (1997).
29. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat. Med. 9(6), 669-676 (2003).
30. Keck PJ, Hauser SD, Krivi G et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246(4935), 1309-1312 (1989).
31. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246(4935), 1306-1309 (1989).
32. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 114(Pt 5), 853-865 (2001).
33. Isakova IA, Baker K, Dutreil M, Dufour J, Gaupp D, Phinney DG. Age- and dose-related effects on MSC engraftment levels and anatomical distribution in the central nervous systems of nonhuman primates: identification of novel MSC subpopulations that respond to guidance cues in brain. Stem Cells 25(12), 3261-3270 (2007).
34. Isner JM, Pieczek A, Schainfeld R et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348(9024), 370-374 (1996).
35. Shigematsu H, Yasuda K, Iwai T et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 17(9), 1152-1161 (2010).
36. Van Belle E, Witzenbichler B, Chen D et al. Potentiated angiogenic effect of scatter factor/ hepatocyte growth factor via induction of vascular endothelial growth factor. Circulation 97(4), 381-390 (1998).
37. Xin X, Yang S, Ingle G et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am. J. Pathol. 158(3), 1111-1120 (2001).
38. Makarevich P, Tsokolaeva Z, Shevelev A et al. Combined transfer of human VEGF165 and HGF genes renders potent angiogenic effect in ischemic skeletal muscle. PLoS ONE 7(6), e38776 (2012).
39. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4(5), 346-358 (2003).
40. Gerritsen ME. HGF and VEGF: a dynamic duo. Circ. Res. 96(3), 272-273 (2005).
41. Min JK, Lee YM, Kim JH et al. Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM1 and VCAM-1 by inhibiting the nuclear factor-kB pathway. Circ. Res. 96(3), 300-307 (2005).
42. Hung SC, Pochampally RR, Chen SC, Hsu SC, Prockop DJ. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells 25(9), 2363-2370 (2007).
43. Mahato RI, Henry J, Narang AS et al. Cationic lipid and polymer-based gene delivery to human pancreatic islets. Mol. Ther. 7(1), 89-100 (2003).
44. Tei K, Matsumoto T, Mifune Y et al. Administrations of peripheral blood CD34- positive cells contribute to medial collateral ligament healing via vasculogenesis. Stem Cells 26(3), 819-830 (2008).
45. Uchijima M, Nagata T, Aoshi T, Koide Y. IFN-g overcomes low responsiveness of myeloid dendritic cells to CpG DNA. Immunol. Cell Biol. 83(1), 92-95 (2005).
46. US NIH Guide for the Care and Use of Laboratory Animals. www.nap.edu/catalog.php?record-id=5140
47. Orientbio. www.orientbio.co.kr